ORCA-1

Nicotine E-Cigarette Cessation Trial

ORCA-V1 will be a multi-center, double-blind, randomized, placebo-controlled, Phase 2 study conducted in male or female adults who are daily nicotine e-cigarette users only, who intend to try to quit vaping and willing to set a quit date that is within 7-14 days from the start of cytisinicline treatment.

A total of approximately 150 subjects will be randomly assigned to one of two arms:

  • Arm A, 12 weeks cytisinicline + behavior support: N=100
  • Arm B, 12 weeks of placebo+ behavior support: N=50